
Quarterly report 2025-Q3
added 11-04-2025
American Well Corporation Financial Ratios 2011-2025 | AMWL
Annual Financial Ratios American Well Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.8 | -0.0 | -0.2 | -6.1 | -10.8 | -0.1 | -0.2 | - | - | - | - | - | - | - |
P/S |
0.7 | 0.1 | 0.2 | 4.3 | 9.9 | 0.1 | 0.1 | - | - | - | - | - | - | - |
EPS |
-13.9 | -47.5 | -19.7 | -0.7 | -2.3 | -2.1 | -1.3 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
63.8 M | -244 M | -362 M | 513 M | 1.61 B | 652 M | 648 M | - | - | - | - | - | - | - |
EBITDA per Share |
-12.3 | -46.5 | -18.2 | -0.64 | -2.19 | -2.11 | -1.23 | - | - | - | - | - | - | - |
EV/EBITDA |
-2.8 | -11.8 | 1.5 | 0.8 | - | - | - | - | - | - | - | |||
PEG |
- | 0.1 | 0.0 | 0.08 | - | - | - | - | - | - | - | |||
P/B |
0.5 | 0.0 | 0.0 | 0.9 | 1.9 | -0.0 | -0.0 | - | - | - | - | - | - | - |
P/CF |
-1.4 | -0.1 | -0.2 | -7.6 | -21.6 | -0.1 | -0.1 | - | - | - | - | - | - | - |
ROE % |
-68.29 | -145.44 | -24.95 | -13.99 | -18.01 | 31.04 | 25.77 | - | - | - | - | - | - | - |
ROA % |
-47.74 | -114.49 | -22.21 | -12.20 | -16.30 | -17.44 | -10.76 | - | - | - | - | - | - | - |
ROCE % |
-71.38 | -149.10 | -25.45 | -14.21 | -18.25 | -24.08 | -13.73 | - | - | - | - | - | - | - |
Current Ratio |
3.6 | 5.4 | 9.1 | 7.8 | 10.6 | 2.1 | 3.4 | - | - | - | - | - | - | - |
DSO |
90.4 | 79.3 | 72.3 | 69.8 | 33.7 | 80.3 | 98.6 | - | - | - | - | - | - | - |
DIO |
11.2 | 17.1 | 18.5 | 20.5 | 10.6 | 14.2 | 15.6 | - | - | - | - | - | - | - |
DPO |
11.6 | 13.4 | 22.1 | 22.1 | 6.7 | 29.7 | 26.3 | - | - | - | - | - | - | - |
Operating Cycle |
101.6 | 96.4 | 90.8 | 90.3 | 44.3 | 94.4 | 114.2 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
90.0 | 82.9 | 68.7 | 68.2 | 37.6 | 64.7 | 87.9 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios American Well Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-2 | -1.24 | -1.19 | - | -2.87 | -3.36 | -4.94 | -9.54 | -6.53 | -1.42 | - | -0.25 | -0.25 | -0.26 | - | -0.2 | -0.15 | -0.16 | - | -0.92 | -1.99 | -0.58 | - | -0.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.23 | -0.76 | -1.44 | - | -2.58 | -2.97 | -4.58 | -9.45 | -6.13 | -1.39 | - | -0.23 | -0.23 | -0.24 | - | -0.18 | -0.14 | -0.15 | - | -0.83 | -1.91 | -0.55 | - | -0.48 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-38.45 | -38.17 | -44.41 | -42.66 | -68.91 | -70.86 | -113.32 | -102.64 | -82.73 | -74.32 | -18.11 | -22.08 | -19.70 | -16.95 | -10.44 | -15.59 | -16.78 | -20.66 | -14.22 | -6.40 | 6.57 | 21.96 | 25.76 | 25.76 | 17.94 | 9.63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-27.53 | -27.52 | -32.29 | -31.98 | -53.46 | -56.44 | -93.37 | -85.91 | -70.11 | -63.30 | -16.01 | -19.48 | -12.10 | -15.05 | -9.43 | -14.01 | -15.13 | -18.47 | -12.65 | -17.45 | -17.67 | -11.38 | -4.80 | -4.80 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-42.60 | -44.62 | -51.27 | -45.12 | -72.70 | -73.85 | -115.62 | -104.33 | -83.18 | -74.48 | -18.25 | -22.52 | -20.36 | -17.52 | -10.61 | -15.86 | -16.84 | -20.87 | -14.53 | -6.15 | 7.49 | 14.66 | 8.38 | 8.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.9 | 4.1 | 3.7 | 3.6 | 3.6 | 3.9 | 4.4 | 5.5 | 6.0 | 6.2 | 9.1 | 9.7 | - | 8.9 | 7.8 | 8.0 | 13.0 | 12.4 | 10.6 | 10.6 | 10.6 | 10.6 | 4.0 | 4.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
88.5 | 80.8 | 98.2 | - | 123.6 | 113.9 | 97.7 | 70.1 | 76.2 | 81.4 | - | 30.1 | 33.3 | 70.0 | - | 55.3 | 55.5 | 65.7 | - | 66.1 | 60.3 | 66.3 | - | 43.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
6.8 | 6.9 | 7.8 | - | 12.3 | 14.1 | 16.0 | 18.4 | 20.2 | 20.2 | - | 8.8 | 10.0 | 19.3 | - | 23.4 | 24.6 | 23.6 | - | 19.8 | 19.0 | 16.9 | - | 7.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
16.5 | 14.9 | 16.5 | - | 16.7 | 14.7 | 12.8 | 10.5 | 13.8 | 16.8 | - | 6.8 | 9.4 | 24.4 | - | 13.6 | 16.1 | 16.1 | - | 12.6 | 12.1 | 17.0 | - | 15.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
95.3 | 87.7 | 106.0 | - | 135.9 | 128.0 | 113.7 | 88.5 | 96.4 | 101.7 | - | 38.9 | 43.4 | 89.3 | - | 78.7 | 80.1 | 89.4 | - | 85.9 | 79.3 | 83.2 | - | 50.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
78.8 | 72.8 | 89.5 | - | 119.1 | 113.4 | 100.9 | 78.0 | 82.6 | 84.8 | - | 32.1 | 34.0 | 64.9 | - | 65.1 | 64.0 | 73.3 | - | 73.3 | 67.2 | 66.2 | - | 34.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company American Well Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
Progyny
PGNY
|
$ 25.95 | 1.72 % | $ 2.23 B | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
Evolent Health
EVH
|
$ 4.15 | 0.24 % | $ 389 M | ||
|
Health Catalyst
HCAT
|
$ 2.43 | 2.1 % | $ 146 M | ||
|
HealthStream
HSTM
|
$ 23.69 | -0.59 % | $ 720 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
OptimizeRx Corporation
OPRX
|
$ 12.53 | -1.8 % | $ 215 M | ||
|
HealthEquity
HQY
|
$ 93.67 | 1.32 % | $ 8.01 B | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
Phreesia
PHR
|
$ 17.12 | 1.63 % | $ 934 M | ||
|
Premier
PINC
|
$ 28.26 | - | $ 2.33 B | ||
|
GoodRx Holdings
GDRX
|
$ 2.76 | -0.36 % | $ 1.06 B | ||
|
So-Young International
SY
|
$ 2.65 | -5.54 % | $ 210 M | ||
|
Omnicell
OMCL
|
$ 46.4 | 1.34 % | $ 2.14 B | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
10x Genomics
TXG
|
$ 16.61 | -0.51 % | $ 1.95 B | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
Zhongchao
ZCMD
|
$ 0.48 | -9.76 % | $ 2.5 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Schrödinger
SDGR
|
$ 18.38 | - | $ 1.34 B | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
Teladoc Health
TDOC
|
$ 7.12 | -1.66 % | $ 1.21 B | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Veeva Systems
VEEV
|
$ 224.44 | 0.51 % | $ 36 B | ||
|
SCWorx Corp.
WORX
|
$ 0.2 | 0.3 % | $ 292 K |